Mersana Therapeutics, Inc.
MRSN
$8.04
-$0.42-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -74.04M | -74.01M | -69.19M | -74.62M | -104.77M |
| Total Depreciation and Amortization | 1.41M | 1.52M | 1.63M | 1.68M | 1.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.64M | 15.15M | 15.96M | 16.94M | 16.86M |
| Change in Net Operating Assets | -21.76M | -21.68M | -30.74M | -39.05M | -46.34M |
| Cash from Operations | -79.76M | -79.01M | -82.34M | -95.05M | -132.56M |
| Capital Expenditure | 0.00 | 0.00 | -132.00K | -518.00K | -990.00K |
| Sale of Property, Plant, and Equipment | 395.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 105.47M | 110.98M | 11.57M | -17.90M | 57.88M |
| Cash from Investing | 105.87M | 110.98M | 11.44M | -18.42M | 56.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.39M | -5.30M | -2.23M | -201.00K | -243.00K |
| Issuance of Common Stock | 257.00K | 428.00K | 6.32M | 6.25M | 6.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -81.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -8.14M | -4.87M | 4.09M | 6.05M | 5.93M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.97M | 27.10M | -66.81M | -107.42M | -69.73M |